Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15314156 | 0.86 | SLC22A1 (0.32) | SLC22A1OPRM1 | |
| SCHEMBL24324108 | 0.86 | SLC22A1 (0.32) | SLC22A1OPRM1 | |
| SCHEMBL19072799 | 0.85 | SLC22A1 (0.37) | SLC22A1OPRM1 | |
| SCHEMBL19243166 | 0.85 | SLC22A1 (0.37) | SLC22A1OPRM1 | |
| SCHEMBL25600030 | 0.81 | SLC22A1 (0.31) | SLC22A1OPRM1 | |
| SCHEMBL8756248 | 0.78 | SLC22A1 (0.34) | SLC22A1OPRM1 | |
| SCHEMBL22018608 | 0.78 | PIK3CD (0.30) | — | |
| SCHEMBL11794150 | 0.78 | HTR2A (0.32) | — | |
| SCHEMBL16079215 | 0.78 | SLC22A1 (0.33) | SLC22A1OPRM1 | |
| SCHEMBL24850079 | 0.77 | ALDH1A1 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4261828-A2 | METHODS AND PROCESSES FOR NON-INVASIVE ASSESSMENT OF GENETIC VARIATIONS | Sequenom, Inc. (US) | 2023-10-18 | — | — | EP | disclosed |
| US-20180105533-A1 | BILE ACID RECEPTOR MODULATORS AND METHODS OF USE THEREOF | CITY OF HOPE | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180105533-A1 | BILE ACID RECEPTOR MODULATORS AND METHODS OF USE THEREOF | NR1H4, GPBAR1, SLC10A2 | SLC22A1 1245/4885OPRM1 495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.